<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pruritus: Therapies for generalized pruritus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pruritus: Therapies for generalized pruritus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pruritus: Therapies for generalized pruritus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara B Fazio, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gil Yosipovitch, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2231418767"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Generalized pruritus can be defined as pruritus that is widespread and not limited to a specific body area. Generalized pruritus can occur in association with multiple conditions, such as dermatologic disorders, liver or kidney dysfunction, malignancy, systemic rheumatic disease, infections, or drug reactions. Pruritus may also occur in the absence of an identifiable etiology. (See  <a class="medical medical_review" href="/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Potential causes'</a>.)</p><p>Generalized pruritus negatively affects quality of life. The condition can result in skin injury, sleep deprivation, and psychologic distress. Successful treatment often requires a multifaceted approach, consisting of treatment of underlying conditions, elimination of aggravating factors, and medical therapy. (See  <a class="medical medical_review" href="/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus", section on 'General approach'</a> and <a class="local">'Antipruritic therapies'</a> below.)</p><p>The management of generalized pruritus will be reviewed here. General principles for the diagnosis and treatment of pruritus and the management of localized pruritus are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus"</a>.)</p><p></p><p>In-depth discussions of specific presentations of pruritus are provided separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/86291.html" rel="external">"Overview of pruritus in palliative care"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3607.html" rel="external">"Pruritus associated with cholestasis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1985.html" rel="external">"Chronic kidney disease-associated pruritus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14989.html" rel="external">"Management of burn wound pain and itching"</a>.)</p><p></p><p class="headingAnchor" id="H2279218353"><span class="h1">GENERAL APPROACH</span><span class="headingEndMark"> — </span>The cause of generalized pruritus influences the approach to treatment. In general, management consists of:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of the underlying disorder (when feasible)</p><p class="bulletIndent1"><span class="glyph">●</span>Elimination of aggravating factors (see <a class="local">'Elimination of aggravating factors'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Therapies to reduce severity of pruritus  (<a class="graphic graphic_table graphicRef50432 graphicRef63221" href="/d/graphic/50432.html" rel="external">table 1A-B</a>) (see <a class="local">'Antipruritic therapies'</a> below)</p><p></p><p class="headingAnchor" id="H1669823101"><span class="h2">Treatment of underlying cause</span><span class="headingEndMark"> — </span>Successful treatment of the underlying cause of pruritus may result in resolution [<a href="#rid1">1</a>]. Thus, identification and treatment of the cause of pruritus is advised, whenever feasible. (See  <a class="medical medical_review" href="/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation"</a>.)</p><p>Occasionally, the cause of pruritus cannot be identified. (See  <a class="medical medical_review" href="/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Chronic pruritus of unknown origin'</a> and <a class="local">'Chronic pruritus of unknown origin'</a> below.)</p><p class="headingAnchor" id="H3785759021"><span class="h2">Elimination of aggravating factors</span><span class="headingEndMark"> — </span>The elimination of aggravating factors for pruritus is an important component of symptom management. Interventions that may be beneficial include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin moisturization </strong>– Dry skin can cause or exacerbate pruritus; thus, all patients with generalized symptoms should be educated on proper skin care. For example, gentle cleansers should be used during bathing, and patients should apply emollients to the skin daily. (See <a class="local">'Xerosis (dry skin)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cool environment </strong>– Symptoms of pruritus may be exacerbated by exposure to heat. Lightweight clothing, air-conditioned environments, and the use of lukewarm (rather than hot) water during showers or baths may reduce symptoms. Lotions that provide a cooling sensation on the skin can provide additional relief. (See  <a class="medical medical_review" href="/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus", section on 'Cooling lotions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of skin irritants </strong>– Direct contact with substances that may irritate the skin, such as wool clothing and household cleansing products, should be avoided.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stress reduction </strong>–<strong> </strong>Stress and other psychogenic factors may induce or aggravate chronic itch [<a href="#rid2">2-5</a>], and stress reduction may help to reduce symptoms. In addition, psychologic support, education on pruritus, and behavioral interventions that minimize symptoms may help patients to cope [<a href="#rid6">6</a>]. Holistic approaches, such as meditation, acupuncture, and yoga, may be useful as adjunctive therapies [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/d/html/1390.html" rel="external">"Overview of the clinical uses of acupuncture"</a> and  <a class="medical medical_review" href="/d/html/87028.html" rel="external">"Overview of yoga"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical interventions </strong>– Scratching may increase symptoms of pruritus, resulting in a perpetual itch-scratch cycle. Occlusion of localized areas of pruritus with Unna boots or other occlusive dressings (eg, hydrocolloid dressings) may help to break this cycle [<a href="#rid9">9</a>]. Keeping fingernails trimmed to a short length may also help to minimize skin damage induced from scratching. (See  <a class="medical medical_review" href="/d/html/15199.html" rel="external">"Compression therapy for the treatment of chronic venous insufficiency", section on 'Unna boot'</a>.)</p><p></p><p class="headingAnchor" id="H2906482347"><span class="h2">Selection of therapy</span><span class="headingEndMark"> — </span>Antipruritic therapies are helpful for the management of pruritus, particularly when elimination of the underlying cause is not feasible or does not result in immediate resolution of symptoms. Although topical antipruritic therapies can be useful adjunctive interventions, satisfactory suppression of generalized pruritus often requires systemic therapy or phototherapy  (<a class="graphic graphic_table graphicRef50432 graphicRef63221" href="/d/graphic/50432.html" rel="external">table 1A-B</a>).</p><p>The cause of generalized pruritus determines the most appropriate approach to treatment. (See <a class="local">'Specific forms of generalized pruritus'</a> below.)</p><p>Initial therapy often consists of a combination of topical therapy (eg, cooling lotions) and nighttime use of sedating antihistamines, as these treatments are widely available and generally well tolerated. Antihistamines also play a key role in the treatment of histamine-mediated pruritus (eg, pruritus related to urticaria or mastocytosis). (See <a class="local">'Topical therapies'</a> below and <a class="local">'Role of antihistamines'</a> below.)</p><p>Antidepressants and anticonvulsants are often incorporated when initial interventions are insufficient. Opioid receptor antagonists and opioid receptor agonists are primarily reserved for severe or refractory pruritus. Failure or intolerance of these therapies may lead to trials of other agents. (See <a class="local">'Antidepressants'</a> below and <a class="local">'Anticonvulsants'</a> below and <a class="local">'Opioid receptor antagonists'</a> below and <a class="local">'Opioid receptor agonists'</a> below and <a class="local">'Other agents'</a> below.)</p><p>Phototherapy is an alternative to systemic therapy that can be useful for pruritus related to ultraviolet light-responsive dermatoses, such as psoriasis [<a href="#rid10">10</a>]. Phototherapy may also be beneficial in the absence of primary skin disease, such as for pruritus related to prurigo nodularis and uremic pruritus. (See <a class="local">'Phototherapy'</a> below.)</p><p class="headingAnchor" id="H469939706"><span class="h1">ANTIPRURITIC THERAPIES</span></p><p class="headingAnchor" id="H1082719092"><span class="h2">Common initial therapies</span><span class="headingEndMark"> — </span>Topical therapies and oral antihistamines are common initial treatments. (See <a class="local">'Other therapies'</a> below.)</p><p class="headingAnchor" id="H80886269"><span class="h3">Topical therapies</span><span class="headingEndMark"> — </span>Topical agents often used for localized pruritus may be helpful as adjuncts to systemic therapy. Application of cooling lotions containing menthol and <a class="drug drug_general" data-topicid="104178" href="/d/drug information/104178.html" rel="external">camphor</a> can provide temporary relief. Other topical therapies used for localized pruritus may also be beneficial for the treatment of focal body areas. (See  <a class="medical medical_review" href="/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus", section on 'Topical therapies'</a>.)</p><p class="headingAnchor" id="H2568446694"><span class="h3">Role of antihistamines</span><span class="headingEndMark"> — </span>Various oral antihistamines have been used for the treatment of pruritus:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – H1 antihistamines are often the first systemic therapies attempted in patients with widespread pruritus due to the relative safety, wide availability, and affordability of these agents. However, with the exception of disorders in which histamine is known to play an important role in pruritus (eg, urticaria and mastocytosis), data on the efficacy of systemic antihistamines for pruritus are limited [<a href="#rid1">1,11</a>]. (See  <a class="medical medical_review" href="/d/html/8101.html" rel="external">"New-onset urticaria", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/4785.html" rel="external">"Cutaneous mastocytosis: Treatment, monitoring, and prognosis", section on 'Antihistamines'</a>.)</p><p></p><p class="bulletIndent1">A sedation-induced decrease in the perception of pruritus is considered the major benefit of antihistamine therapy in the treatment of other disorders. This approach, which involves use of sedating H1 antihistamines such as <a class="drug drug_general" data-topicid="8544" href="/d/drug information/8544.html" rel="external">hydroxyzine</a> and <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>, may be particularly useful for patients who experience nocturnal exacerbations of pruritus [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a> and  <a class="medical medical_review" href="/d/html/15762.html" rel="external">"Exanthematous (maculopapular) drug eruption", section on 'Symptomatic treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for use</strong> – Oral H1 antihistamines function through the blockage of H1 receptors on afferent C nerve fibers and may also inhibit the release of pruritic mediators from mast cells when administered at high doses [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/8101.html" rel="external">"New-onset urticaria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Sedating antihistamines, such as <a class="drug drug_general" data-topicid="8544" href="/d/drug information/8544.html" rel="external">hydroxyzine</a> and <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>, are often given at night because drowsiness is common, and sedation during the day is generally unwanted and may be hazardous, particularly in older adult patients. A typical adult dose is 25 to 50 mg of hydroxyzine or diphenhydramine before bed. Other potential adverse effects include xerostomia and, at high doses, respiratory depression. (See  <a class="drug drug_general" href="/d/drug information/8544.html" rel="external">"Hydroxyzine: Drug information"</a>.)</p><p></p><p class="headingAnchor" id="H3126640868"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>Oral antidepressants, anticonvulsants, phototherapy, opioid receptor antagonists, opioid receptor agonists, and other agents may improve pruritus  (<a class="graphic graphic_table graphicRef63221" href="/d/graphic/63221.html" rel="external">table 1B</a>). (See <a class="local">'Selection of therapy'</a> above.)</p><p class="headingAnchor" id="H1159034803"><span class="h3">Antidepressants</span><span class="headingEndMark"> — </span>Oral antidepressants, such as <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a> and selective serotonin reuptake inhibitors (eg, <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>), and tricyclic antidepressants (eg, <a class="drug drug_general" data-topicid="9390" href="/d/drug information/9390.html" rel="external">doxepin</a>) may be useful for the treatment of chronic pruritus [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Overall, there is the greatest amount of literature support for antidepressant benefit in chronic pruritus related to malignancies, cholestasis, and chronic kidney disease [<a href="#rid13">13</a>]. Additional randomized trials will be helpful for clarifying indications for antidepressant therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for use</strong> – Benefit from oral antidepressants is postulated to result from the effects of these drugs on serotonin and histamine levels. </p><p></p><p class="bulletIndent1">However, randomized trials are few, and most data on the efficacy of these agents come from open-label studies, case reports, and case series [<a href="#rid13">13</a>]. As an example, in a randomized trial of 110 patients treated with intrathecal <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, prophylactic <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a> was associated with a reduced incidence of pruritus after morphine therapy [<a href="#rid14">14</a>]. In addition, in an open-label study in which 72 patients with severe, chronic pruritus were treated with <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> or <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a>, 68 percent of patients had a mild, good, or very good response to treatment [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1">In a randomized, cross-over trial that included 24 patients on hemodialysis given either <a class="drug drug_general" data-topicid="9390" href="/d/drug information/9390.html" rel="external">doxepin</a> (20 mg per day) or placebo for one week and switched to the converse agent for a second week, complete resolution of pruritus was achieved in 14 patients (58 percent) during doxepin therapy compared with only 2 patients (8 percent) in the placebo group [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Typical dose ranges for adults are reviewed in a table  (<a class="graphic graphic_table graphicRef63221" href="/d/graphic/63221.html" rel="external">table 1B</a>). Antipruritic benefit may be evident within the first few days of treatment for <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>; in contrast, other benefit from other antidepressants may not occur for several weeks. Adverse effects are reviewed in detail separately  (<a class="graphic graphic_table graphicRef62488" href="/d/graphic/62488.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/85816.html" rel="external">"Atypical antidepressants: Pharmacology, administration, and side effects", section on 'Mirtazapine'</a> and  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Side effects'</a>.)</p><p></p><p class="headingAnchor" id="H1396162533"><span class="h3">Anticonvulsants</span><span class="headingEndMark"> — </span>Anticonvulsant therapies used for pruritus include <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a>:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> may be particularly useful in forms of neuropathic pruritus related to nerve entrapment disorders, such as brachioradial pruritus and notalgia paresthetica [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus", section on 'Peripheral neuropathic itch'</a>.)</p><p></p><p class="bulletIndent1">There have been case reports suggesting that <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> may also be beneficial in patients with idiopathic pruritus [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for use</strong> – Anticonvulsants such as <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> are structural analogs of the neurotransmitter gamma-aminobutyric acid (GABA). The mechanism through which these agents improve pruritus is unknown. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Dosing of <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> for pruritus in adults is provided in a table  (<a class="graphic graphic_table graphicRef63221" href="/d/graphic/63221.html" rel="external">table 1B</a>). Doses are titrated upward based upon response and tolerability. Once an effective dose is reached, improvement is usually evident immediately. Dose adjustments are necessary for patients with renal insufficiency. Dizziness and sedation are common adverse effects. (See  <a class="drug drug_general" href="/d/drug information/8483.html" rel="external">"Gabapentin: Drug information"</a> and  <a class="drug drug_general" href="/d/drug information/9473.html" rel="external">"Pregabalin: Drug information"</a>.)</p><p></p><p class="headingAnchor" id="H891553618"><span class="h3">Phototherapy</span><span class="headingEndMark"> — </span>Phototherapy with ultraviolet radiation is an option for the treatment of pruritus [<a href="#rid19">19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Although phototherapy has been most extensively used for skin lesion resolution in inflammatory dermatoses, such as psoriasis, it may also improve pruritus in the absence of a primary skin disease, such as in cases of prurigo nodularis [<a href="#rid20">20-22</a>], uremia [<a href="#rid23">23-25</a>], polycythemia vera [<a href="#rid26">26,27</a>], psychogenic excoriations [<a href="#rid28">28</a>], and notalgia paresthetica [<a href="#rid29">29</a>]. Advantages of phototherapy include the ability to use it in patients with contraindications to systemic agents, such as some older adult patients taking multiple medications [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for use</strong> – The mechanism through which ultraviolet light reduces pruritus is unknown but may involve effects on epidermal opioid systems, epidermal cytokines, cutaneous mast cells, or epidermal nerve fibers [<a href="#rid12">12,25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Multiple forms of phototherapy have been used for pruritus, including broadband ultraviolet B (UVB), narrowband ultraviolet B (NBUVB), psoralen plus ultraviolet A (PUVA), and ultraviolet A1 (UVA1). The efficacies of specific types of phototherapy vary among different disorders and individual patients [<a href="#rid19">19,31,32</a>]. In our experience, at least two months of treatment is often necessary for improvement. (See  <a class="medical medical_review" href="/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a> and  <a class="medical medical_review" href="/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a> and  <a class="medical medical_review" href="/d/html/91676.html" rel="external">"UVA1 phototherapy"</a>.)</p><p></p><p class="bulletIndent1">Potential side effects include skin burning or blistering and a potential increase in risk for skin cancer.</p><p></p><p class="headingAnchor" id="H126516474"><span class="h3">Opioid receptor antagonists</span><span class="headingEndMark"> — </span>The mu-opioid receptor antagonists, such as <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a>, <a class="drug drug_general" data-topicid="135038" href="/d/drug information/135038.html" rel="external">nalmefene</a>, and <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a>, appear to be effective against some forms of pruritus [<a href="#rid33">33,34</a>]. <a class="drug drug_general" data-topicid="9444" href="/d/drug information/9444.html" rel="external">Methylnaltrexone</a> is a peripherally acting opioid receptor antagonist that may have benefit in the management of pruritus [<a href="#rid35">35,36</a>]. However, further studies are necessary to determine the efficacy of this drug:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – In randomized trials, opioid receptor antagonists have been beneficial for the treatment of pruritus secondary to cholestasis, chronic urticaria, atopic dermatitis, and epidural <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> administration [<a href="#rid33">33,34,37</a>]. In addition, cases in which opioid receptor antagonists were used successfully for the treatment of prurigo nodularis, mycosis fungoides, aquagenic pruritus, and other pruritic disorders have been reported [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">Use of opioid receptor antagonists for cholestatic pruritus and uremic pruritus is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/3607.html" rel="external">"Pruritus associated with cholestasis", section on 'Opioid antagonists'</a> and  <a class="medical medical_review" href="/d/html/1985.html" rel="external">"Chronic kidney disease-associated pruritus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for use</strong> – Activation of mu-opioid receptors in the central nervous system may contribute to itch through suppression of the inhibitory effect of pain-transmitting neurons on pruriceptive neurons [<a href="#rid12">12,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Dosing for <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> for adults typically ranges from 12.5 to 50 mg per day. Use of naltrexone and other opioid receptor antagonists in cholestatic pruritus and uremic pruritus is reviewed separately. (See  <a class="medical medical_review" href="/d/html/3607.html" rel="external">"Pruritus associated with cholestasis"</a> and  <a class="medical medical_review" href="/d/html/1985.html" rel="external">"Chronic kidney disease-associated pruritus"</a>.)</p><p></p><p class="bulletIndent1">Precipitation of opioid withdrawal is a common adverse effect. Patients develop symptoms such as agitation, nausea, vomiting, and anxiety. Other adverse effects of opioid receptor antagonists are reviewed in detail separately. (See  <a class="drug drug_general" href="/d/drug information/9679.html" rel="external">"Naltrexone: Drug information"</a> and  <a class="drug drug_general" href="/d/drug information/9678.html" rel="external">"Naloxone: Drug information"</a>.)</p><p></p><p class="headingAnchor" id="H4078385471"><span class="h3">Opioid receptor agonists</span><span class="headingEndMark"> — </span>Examples of kappa-opioid receptor agonists used for pruritus include <a class="drug drug_general" data-topicid="9179" href="/d/drug information/9179.html" rel="external">butorphanol</a>, <a class="drug drug_general" data-topicid="9676" href="/d/drug information/9676.html" rel="external">nalbuphine</a>, nalfurafine, and <a class="drug drug_general" data-topicid="132520" href="/d/drug information/132520.html" rel="external">difelikefalin</a>. Nalfurafine is not available in the United States but is available in Japan. Difelikefalin has demonstrated efficacy for uremic pruritus (see  <a class="medical medical_review" href="/d/html/1985.html" rel="external">"Chronic kidney disease-associated pruritus"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Opioid receptor agonists play a role in the treatment of uremic pruritus. These agents have also been used for the treatment of other forms of intractable pruritus [<a href="#rid39">39,40</a>].</p><p></p><p class="bulletIndent1">Use of opioid receptor agonists in patients with uremic pruritus is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/1985.html" rel="external">"Chronic kidney disease-associated pruritus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for use</strong> – Activation of kappa-opioid receptors in the central nervous system may inhibit itch [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9676" href="/d/drug information/9676.html" rel="external">Nalbuphine</a>, a kappa-opioid agonist and partial mu-opioid agonist, has been shown to reduce pruritus induced by mu-opioid agonist medications, including epidural <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> [<a href="#rid41">41</a>]. Nalbuphine is under investigation for efficacy for prurigo nodularis.</p><p></p><p class="bulletIndent1">In a phase 3, placebo-controlled trial involving 337 patients with pruritus related to chronic kidney disease, oral nalfurafine reduced itch [<a href="#rid42">42</a>]. A randomized, phase 3 trial supports benefit of <a class="drug drug_general" data-topicid="132520" href="/d/drug information/132520.html" rel="external">difelikefalin</a> for uremic pruritus [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/1985.html" rel="external">"Chronic kidney disease-associated pruritus"</a>.)</p><p></p><p class="bulletIndent1">In a case series of five patients with intractable pruritus due to inflammatory skin disease or systemic disorders, intranasal <a class="drug drug_general" data-topicid="9179" href="/d/drug information/9179.html" rel="external">butorphanol</a> was associated with rapid and marked improvement [<a href="#rid39">39</a>]. Most patients responded to a dose of 1 mg per day. Other case series suggest benefit of butorphanol for cholestatic itch and intractable itch [<a href="#rid40">40,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="9179" href="/d/drug information/9179.html" rel="external">Butorphanol</a> can be administered intranasally; typical doses for pruritus in adults range from 1 to 4 mg per day. Common adverse effects include drowsiness, dizziness, insomnia, nausea, vomiting, and nasal congestion. Use of other opioid receptor agonists for uremic pruritus is reviewed separately. (See  <a class="medical medical_review" href="/d/html/1985.html" rel="external">"Chronic kidney disease-associated pruritus"</a>.)</p><p></p><p class="headingAnchor" id="H3125949185"><span class="h3">Other agents</span><span class="headingEndMark"> — </span>Additional drugs that have been used for refractory pruritus include <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a> and <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a>. Immunomodulatory agents, including immunosuppressants and biologic agents, may also be of benefit for specific forms of pruritus.</p><p class="headingAnchor" id="H3788756572"><span class="h4">Aprepitant</span><span class="headingEndMark"> — </span>Improvement in refractory pruritus has been reported in patients treated with <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a>, a neurokinin receptor 1 antagonist [<a href="#rid45">45-51</a>]. The efficacy of this drug may be related to inhibition of the binding of substance P (a mediator of pruritus) to the neurokinin receptor. Additional studies are necessary to determine the role of aprepitant in the management of patients with pruritus.</p><p class="headingAnchor" id="H2562359366"><span class="h4">Thalidomide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">Thalidomide</a>, an agent occasionally used for the treatment of various refractory autoimmune and inflammatory skin diseases, may be useful for the treatment of refractory, chronic pruritus. Efficacy may occur through a variety of mechanisms; thalidomide has central depressant, anti-inflammatory, immunomodulatory, and neuromodulatory properties [<a href="#rid52">52</a>]. Benefit for pruritus has been reported in patients with a variety of disorders associated with chronic pruritus, most commonly prurigo nodularis [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/13667.html" rel="external">"Prurigo nodularis", section on 'Systemic therapies'</a>.)</p><p><a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">Thalidomide</a> is associated with side effects, including sedation, peripheral neuropathy, thromboembolism, skin eruptions, and dizziness. The drug is teratogenic and should not be administered to pregnant patients. In the United States, participation in a Risk Evaluation and Mitigation Strategy (REMS) program is necessary to obtain thalidomide.</p><p class="headingAnchor" id="H2587405138"><span class="h4">Immunomodulating agents</span><span class="headingEndMark"> — </span>In patients with inflammatory skin diseases, such as atopic dermatitis or psoriasis, systemic therapy for skin disease with immunosuppressants or biologic agents may lead to improvement in skin manifestations and associated pruritus.</p><p>Th17-related cytokines have emerged as novel targets for treatment of itch in psoriasis. <a class="drug drug_general" data-topicid="99569" href="/d/drug information/99569.html" rel="external">Secukinumab</a>, <a class="drug drug_general" data-topicid="107448" href="/d/drug information/107448.html" rel="external">ixekizumab</a>, and <a class="drug drug_general" data-topicid="112051" href="/d/drug information/112051.html" rel="external">brodalumab</a> are human monoclonal antibodies targeting interleukin (IL) 17A used for the treatment of moderate to severe psoriasis. Randomized trials support the efficacy of these agents for improving itch in patients with moderate to severe plaque psoriasis [<a href="#rid53">53-55</a>].</p><p><a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">Dupilumab</a>, an IL-4 and IL-13 inhibitor for atopic dermatitis, improves atopic itch rapidly and has been associated with improvement of pruritus in other conditions in case series, such as prurigo nodularis, hand eczema, bullous pemphigoid, chronic spontaneous urticaria, and anogenital itch [<a href="#rid56">56,57</a>]. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>.)</p><p class="headingAnchor" id="H2831558190"><span class="h4">Medical marijuana</span><span class="headingEndMark"> — </span>In a case report, medical marijuana therapy was associated with improvement and eventual resolution of pruritus in a patient with pruritus associated with lichen amyloidosis secondary to primary sclerosing cholangitis [<a href="#rid58">58</a>]. The patient experienced mild sedation as a side effect.</p><p class="headingAnchor" id="H10270363"><span class="h1">SPECIFIC FORMS OF GENERALIZED PRURITUS</span></p><p class="headingAnchor" id="H1067080009"><span class="h2">Dermatologic disorders</span><span class="headingEndMark"> — </span>As with localized pruritus, widespread pruritus related to extensive skin disease often improves with successful treatment of the skin disease. Inflammatory skin diseases and xerosis are common causes of generalized pruritus.</p><p class="headingAnchor" id="H583889129"><span class="h3">Inflammatory skin disease</span><span class="headingEndMark"> — </span>Therapeutic approaches to common inflammatory skin diseases associated with generalized pruritus are reviewed separately. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>Atopic dermatitis (see  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asteatotic and nummular eczema (see  <a class="medical medical_review" href="/d/html/1727.html" rel="external">"Overview of dermatitis (eczematous dermatoses)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psoriasis (see  <a class="medical medical_review" href="/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a> and  <a class="medical medical_review" href="/d/html/112983.html" rel="external">"Psoriasis in children: Management of chronic plaque psoriasis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Scabies (see  <a class="medical medical_review" href="/d/html/114369.html" rel="external">"Scabies: Management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urticaria (see  <a class="medical medical_review" href="/d/html/8101.html" rel="external">"New-onset urticaria"</a> and  <a class="medical medical_review" href="/d/html/8106.html" rel="external">"Chronic spontaneous urticaria: Standard management and patient education"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pruritic dermatoses of pregnancy (see  <a class="medical medical_review" href="/d/html/5564.html" rel="external">"Dermatoses of pregnancy"</a>)</p><p></p><p class="headingAnchor" id="H4278803796"><span class="h3">Xerosis (dry skin)</span><span class="headingEndMark"> — </span>Xerosis is common in older adults and in people living in northern climates, where home heating during the winter results in very low relative humidity. Interventions that may improve xerosis and related pruritus include [<a href="#rid1">1,59</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of mild cleansers </strong>– Traditional soaps alkalinize the skin and can cause damage to the natural skin moisture barrier, thereby worsening xerosis and aggravating pruritus. Synthetic detergent (syndet) cleansers or other mild cleansers are preferred. Syndet cleansers typically have a low pH that approximates the normal acidic pH of the skin. They tend to be less irritating than traditional soaps and may optimize skin barrier function [<a href="#rid60">60,61</a>].</p><p></p><p class="bulletIndent1">In addition, there is some evidence to suggest that serine proteases involved in the pathogenesis of pruritus are inhibited by low pH agents [<a href="#rid62">62</a>]. Low pH topical agents may reduce activity of serine proteases, such as mast cell tryptase, which is known to activate protease-activated receptor 2 (PAR2) on skin nerve fibers [<a href="#rid62">62</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine use of skin moisturizers </strong>– Daily use of moisturizers, which contain substances that promote epidermal hydration (humectants such as <a class="drug drug_general" data-topicid="8959" href="/d/drug information/8959.html" rel="external">glycerin</a>, lactic acid, or topical <a class="drug drug_general" data-topicid="10031" href="/d/drug information/10031.html" rel="external">urea</a>) and/or substances that reduce water loss from the skin (occlusives such as petrolatum), is a crucial component of xerosis management [<a href="#rid63">63,64</a>]. Moisturizers and/or occlusives should be applied immediately after bathing and gentle drying of the skin.</p><p></p><p class="bulletIndent1">Thicker, greasier products tend to be more effective for maintaining skin moisture but may be perceived as uncomfortable or unsightly by some patients. Greasier preparations may be better accepted by patients for use at bedtime.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of excessive and aggressive skin washing </strong>– Excessive washing (eg, multiple times per day) can worsen dry skin, particularly when hot water is used to bathe. Lukewarm or warm water is preferable for bathing, and patients should be instructed to avoid aggressive scrubbing of the skin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of a humidifier </strong>– Increasing the relative humidity of indoor air during the winter may be beneficial for patients who are prone to xerosis.</p><p></p><p>Asteatotic eczema that results from xerosis may be treated with topical corticosteroids. (See  <a class="medical medical_review" href="/d/html/1727.html" rel="external">"Overview of dermatitis (eczematous dermatoses)", section on 'Asteatotic eczema'</a>.)</p><p class="headingAnchor" id="H3942699863"><span class="h3">Prurigo nodularis</span><span class="headingEndMark"> — </span>Prurigo nodularis is a disorder characterized by the development of multiple symmetrically distributed, firm, pruritic nodules in patients with chronic pruritus. Treatment involves measures to control pruritus, disrupt the itch-scratch cycle, and improve skin lesions. The treatment of prurigo nodularis is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/13667.html" rel="external">"Prurigo nodularis"</a>.)</p><p class="headingAnchor" id="H849152293"><span class="h2">Systemic disorders</span><span class="headingEndMark"> — </span>Generalized pruritus may occur in association with disorders such as renal disease (uremic pruritus), liver disease (cholestatic pruritus), endocrine disease (thyroid disease or diabetes), hematologic malignancies, infection (eg, HIV), systemic rheumatic disease (eg, dermatomyositis, systemic sclerosis, Sjögren's syndrome), multiple sclerosis, and psychiatric disorders. (See  <a class="medical medical_review" href="/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Systemic disorders'</a>.)</p><p>Specific approaches to some of these conditions are reviewed separately.</p><p>Organ dysfunction:</p><p class="bulletIndent1"><span class="glyph">●</span>Uremic pruritus (see  <a class="medical medical_review" href="/d/html/1985.html" rel="external">"Chronic kidney disease-associated pruritus"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cholestatic pruritus (see  <a class="medical medical_review" href="/d/html/3607.html" rel="external">"Pruritus associated with cholestasis"</a>)</p><p></p><p>Hematologic disorders, cutaneous lymphoma, and paraneoplastic pruritus:</p><p class="bulletIndent1"><span class="glyph">●</span>Polycythemia vera (see  <a class="medical medical_review" href="/d/html/4534.html" rel="external">"Polycythemia vera and secondary polycythemia: Treatment and prognosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mycosis fungoides (see  <a class="medical medical_review" href="/d/html/4757.html" rel="external">"Treatment of early stage (IA to IIA) mycosis fungoides"</a> and  <a class="medical medical_review" href="/d/html/4759.html" rel="external">"Treatment of advanced stage (IIB to IV) mycosis fungoides", section on 'Pruritus'</a> and  <a class="medical medical_review" href="/d/html/16616.html" rel="external">"Treatment of Sézary syndrome", section on 'Pruritus'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Various hematologic disorders and malignancies (see  <a class="medical medical_review" href="/d/html/86291.html" rel="external">"Overview of pruritus in palliative care", section on 'Hematologic diseases, tumor infiltration, paraneoplastic pruritus'</a>)</p><p></p><p>Systemic rheumatic disease:</p><p class="bulletIndent1"><span class="glyph">●</span>Dermatomyositis (see  <a class="medical medical_review" href="/d/html/13771.html" rel="external">"Cutaneous dermatomyositis in adults: Overview and initial management", section on 'Interventions for pruritus'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic sclerosis (see  <a class="medical medical_review" href="/d/html/7542.html" rel="external">"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults", section on 'Pruritus'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sjögren's syndrome (see  <a class="medical medical_review" href="/d/html/113735.html" rel="external">"Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations", section on 'Pruritus'</a>)</p><p></p><p>Psychiatric disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>Psychiatric disorders (see  <a class="medical medical_review" href="/d/html/13698.html" rel="external">"Skin picking (excoriation) disorder and related disorders"</a> and  <a class="medical medical_review" href="/d/html/15747.html" rel="external">"Treatment of delusional infestation"</a>)</p><p></p><p class="headingAnchor" id="H1471012850"><span class="h2">Drug-related pruritus</span><span class="headingEndMark"> — </span>Medication adverse reactions and substance use disorders (opioids, cocaine, amphetamines) may cause generalized pruritus.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Pruritus'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4469.html" rel="external">"Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Pruritus'</a>.)</p><p></p><p class="headingAnchor" id="H3678515052"><span class="h2">Chronic pruritus of unknown origin</span><span class="headingEndMark"> — </span>Chronic pruritus of unknown origin is defined as chronic pruritus in the absence of an identifiable etiology [<a href="#rid65">65</a>]. The best approach to generalized chronic pruritus of unknown origin is unclear [<a href="#rid66">66</a>]. Our approach to the treatment of these patients is similar to the approach described here. (See <a class="local">'Selection of therapy'</a> above.)</p><p class="headingAnchor" id="H1334726962"><span class="h1">EMERGING THERAPIES</span><span class="headingEndMark"> — </span>Emerging therapies for pruritus include Janus kinase (JAK) inhibitors and other agents:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Janus kinase inhibitors</strong> – <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">Tofacitinib</a>, a specific Janus kinase (JAK) 1 and JAK3 inhibitor primarily used for the treatment of rheumatoid arthritis, has demonstrated antipruritic effects in both atopic dermatitis and psoriasis [<a href="#rid67">67,68</a>]. <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">Upadacitinib</a> and <a class="drug drug_general" data-topicid="134831" href="/d/drug information/134831.html" rel="external">abrocitinib</a>, JAK1 inhibitors, have demonstrated antipruritic effects in patients with atopic dermatitis in randomized trials [<a href="#rid69">69-73</a>]. <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">Baricitinib</a> selectively inhibits JAK1 and JAK2 and was associated with decreased pruritus of atopic dermatitis in phase 2 trials [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>.)</p><p></p><p class="bulletIndent1">Inhibition of interleukin (IL) 31, a cytokine that has been implicated in pruritus and has been found at increased levels in patients with atopic dermatitis and cutaneous T cell lymphoma, prurigo nodularis, stasis dermatitis, and bullous pemphigoid, may represent an additional therapeutic pathway [<a href="#rid75">75-79</a>]. Studies with nemolizumab, an IL-31 receptor antibody, had shown significant, antipruritic effect in prurigo nodularis in a phase 2 study [<a href="#rid77">77</a>] and atopic dermatitis in a phase 3 study [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serlopitant</strong> – Phase 2, randomized trials support efficacy of serlopitant, an investigational neurokinin 1 receptor antagonist, for psoriatic pruritus and chronic pruritus [<a href="#rid81">81,82</a>]. However, serlopitant was not effective for pruritus associated with prurigo nodularis in phase 3, randomized trials [<a href="#rid83">83</a>].</p><p></p><p class="headingAnchor" id="H2943641022"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118799.html" rel="external">"Society guideline links: Pruritus"</a>.)</p><p class="headingAnchor" id="H1319240060"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Generalized pruritus, widespread pruritus that is not limited to a specific body area, can occur in association with a variety of disorders. Treatment of pruritus is generally indicated because of the profound, negative impact of pruritus on quality of life. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach</strong> – A multifaceted, therapeutic approach is often indicated for generalized pruritus. Key components include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of the underlying disorder</p><p class="bulletIndent2"><span class="glyph">•</span>Elimination of aggravating factors</p><p class="bulletIndent2"><span class="glyph">•</span>Antipruritic therapies  (<a class="graphic graphic_table graphicRef50432 graphicRef63221" href="/d/graphic/50432.html" rel="external">table 1A-B</a>)</p><p></p><p class="bulletIndent1">The cause of pruritus influences the approach to therapy. (See <a class="local">'General approach'</a> above and <a class="local">'Specific forms of generalized pruritus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common initial therapies</strong> – Topical therapies (eg, cooling lotions) and oral sedating antihistamines are common initial medical interventions for pruritus because of the well-tolerated natures of these therapies. The sedating effects of first-generation antihistamines are beneficial for patients with difficulty sleeping due to pruritus. The role for nonsedating antihistamines in pruritus that is not primarily histamine mediated is less clear. (See <a class="local">'Common initial therapies'</a> above and <a class="local">'Role of antihistamines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other therapies</strong> – Other interventions may be helpful for pruritus that cannot be managed with common initial therapies. Subsequent therapies include anticonvulsants (eg, <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a>) and antidepressants (eg, <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>). Phototherapy is an alternative approach that may be beneficial for some patients. Opioid receptor antagonists, opioid receptor agonists, and other systemic agents are typically reserved for severe or refractory pruritus. (See <a class="local">'Other therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic pruritus of unknown origin</strong> – The cause of pruritus cannot always be identified, contributing to uncertainty regarding the best approach to treatment. For patients with chronic pruritus of unknown origin that cannot be adequately controlled with topical therapy and nighttime administration of oral sedating antihistamines, we suggest a trial of oral antidepressant or anticonvulsant therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Opioid receptor antagonists and opioid receptor agonists are options for severe pruritus of unknown origin that fails to respond to antidepressant and anticonvulsant therapy.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med 2013; 368:1625.</a></li><li class="breakAll">Gieler U, Niemeier V, Brosig B, Kupfer J. Psychosomatic aspects of pruritus. In: Itch: Basic Mechanisms and Therapy, Yosipovitch G, Greaves MW, Fleischer AB Jr, McGlone F (Eds), Marcel Dekker, 2004. p.343.</li><li><a class="nounderline abstract_t">Yamamoto Y, Yamazaki S, Hayashino Y, et al. Association between frequency of pruritic symptoms and perceived psychological stress: a Japanese population-based study. Arch Dermatol 2009; 145:1384.</a></li><li><a class="nounderline abstract_t">Yosipovitch G, Goon A, Wee J, et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143:969.</a></li><li><a class="nounderline abstract_t">Yosipovitch G, Goon AT, Wee J, et al. Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus. Int J Dermatol 2002; 41:212.</a></li><li><a class="nounderline abstract_t">van Os-Medendorp H, Ros WJ, Eland-de Kok PC, et al. Effectiveness of the nursing programme 'Coping with itch': a randomized controlled study in adults with chronic pruritic skin disease. Br J Dermatol 2007; 156:1235.</a></li><li><a class="nounderline abstract_t">Pfab F, Huss-Marp J, Gatti A, et al. Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema - a blinded, randomized, placebo-controlled, crossover trial. Allergy 2010; 65:903.</a></li><li><a class="nounderline abstract_t">Kim KH, Lee MS, Choi SM. Acupuncture for treating uremic pruritus in patients with end-stage renal disease: a systematic review. J Pain Symptom Manage 2010; 40:117.</a></li><li><a class="nounderline abstract_t">Tuerk MJ, Koo J. A practical review and update on the management of pruritus sine materia. Cutis 2008; 82:187.</a></li><li><a class="nounderline abstract_t">Väkevä L, Niemelä S, Lauha M, et al. Narrowband ultraviolet B phototherapy improves quality of life of psoriasis and atopic dermatitis patients up to 3 months: Results from an observational multicenter study. Photodermatol Photoimmunol Photomed 2019; 35:332.</a></li><li><a class="nounderline abstract_t">O'Donoghue M, Tharp MD. Antihistamines and their role as antipruritics. Dermatol Ther 2005; 18:333.</a></li><li><a class="nounderline abstract_t">Metz M, Ständer S. Chronic pruritus--pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol 2010; 24:1249.</a></li><li><a class="nounderline abstract_t">Kouwenhoven TA, van de Kerkhof PCM, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: A systematic review. J Am Acad Dermatol 2017; 77:1068.</a></li><li><a class="nounderline abstract_t">Sheen MJ, Ho ST, Lee CH, et al. Prophylactic mirtazapine reduces intrathecal morphine-induced pruritus. Br J Anaesth 2008; 101:711.</a></li><li><a class="nounderline abstract_t">Ständer S, Böckenholt B, Schürmeyer-Horst F, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009; 89:45.</a></li><li><a class="nounderline abstract_t">Pour-Reza-Gholi F, Nasrollahi A, Firouzan A, et al. Low-dose doxepin for treatment of pruritus in patients on hemodialysis. Iran J Kidney Dis 2007; 1:34.</a></li><li><a class="nounderline abstract_t">Matsuda KM, Sharma D, Schonfeld AR, Kwatra SG. Gabapentin and pregabalin for the treatment of chronic pruritus. J Am Acad Dermatol 2016; 75:619.</a></li><li><a class="nounderline abstract_t">Yesudian PD, Wilson NJ. Efficacy of gabapentin in the management of pruritus of unknown origin. Arch Dermatol 2005; 141:1507.</a></li><li><a class="nounderline abstract_t">Rivard J, Lim HW. Ultraviolet phototherapy for pruritus. Dermatol Ther 2005; 18:344.</a></li><li><a class="nounderline abstract_t">Hammes S, Hermann J, Roos S, Ockenfels HM. UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis. J Eur Acad Dermatol Venereol 2011; 25:799.</a></li><li><a class="nounderline abstract_t">Bruni E, Caccialanza M, Piccinno R. Phototherapy of generalized prurigo nodularis. Clin Exp Dermatol 2010; 35:549.</a></li><li><a class="nounderline abstract_t">Tamagawa-Mineoka R, Katoh N, Ueda E, Kishimoto S. Narrow-band ultraviolet B phototherapy in patients with recalcitrant nodular prurigo. J Dermatol 2007; 34:691.</a></li><li><a class="nounderline abstract_t">Ada S, Seçkin D, Budakoğlu I, Ozdemir FN. Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study. J Am Acad Dermatol 2005; 53:149.</a></li><li><a class="nounderline abstract_t">Gilchrest BA, Rowe JW, Brown RS, et al. Relief of uremic pruritus with ultraviolet phototherapy. N Engl J Med 1977; 297:136.</a></li><li><a class="nounderline abstract_t">Ko MJ, Yang JY, Wu HY, et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. Br J Dermatol 2011; 165:633.</a></li><li><a class="nounderline abstract_t">Madkan VK, Bandow GD, Koo JY. Resolution of pruritus secondary to polycythemia vera in a patient treated with narrow-band ultraviolet B phototherapy. J Dermatolog Treat 2005; 16:56.</a></li><li><a class="nounderline abstract_t">Baldo A, Sammarco E, Plaitano R, et al. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br J Dermatol 2002; 147:979.</a></li><li><a class="nounderline abstract_t">Ozden MG, Aydin F, Sentürk N, et al. Narrow-band ultraviolet B as a potential alternative treatment for resistant psychogenic excoriation: an open-label study. Photodermatol Photoimmunol Photomed 2010; 26:162.</a></li><li><a class="nounderline abstract_t">Pérez-Pérez L, Allegue F, Fabeiro JM, et al. Notalgia paresthesica successfully treated with narrow-band UVB: report of five cases. J Eur Acad Dermatol Venereol 2010; 24:730.</a></li><li><a class="nounderline abstract_t">Patel T, Yosipovitch G. The management of chronic pruritus in the elderly. Skin Therapy Lett 2010; 15:5.</a></li><li><a class="nounderline abstract_t">Hsu MM, Yang CC. Uraemic pruritus responsive to broadband ultraviolet (UV) B therapy does not readily respond to narrowband UVB therapy. Br J Dermatol 2003; 149:888.</a></li><li><a class="nounderline abstract_t">Gambichler T, Hyun J, Sommer A, et al. A randomised controlled trial on photo(chemo)therapy of subacute prurigo. Clin Exp Dermatol 2006; 31:348.</a></li><li><a class="nounderline abstract_t">Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol 2010; 63:680.</a></li><li><a class="nounderline abstract_t">Ekelem C, Juhasz M, Khera P, Mesinkovska NA. Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review. JAMA Dermatol 2019; 155:229.</a></li><li><a class="nounderline abstract_t">Yuan CS, Foss JF, O'Connor M, et al. Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend 1998; 52:161.</a></li><li><a class="nounderline abstract_t">Moss J, Rosow CE. Development of peripheral opioid antagonists' new insights into opioid effects. Mayo Clin Proc 2008; 83:1116.</a></li><li><a class="nounderline abstract_t">Penning JP, Samson B, Baxter AD. Reversal of epidural morphine-induced respiratory depression and pruritus with nalbuphine. Can J Anaesth 1988; 35:599.</a></li><li><a class="nounderline abstract_t">Raap U, Ständer S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Allergy Clin Immunol 2011; 11:420.</a></li><li><a class="nounderline abstract_t">Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006; 54:527.</a></li><li><a class="nounderline abstract_t">Khanna R, Kwon CD, Patel SP, et al. Intranasal butorphanol rescue therapy for the treatment of intractable pruritus: A case series from the Johns Hopkins Itch Clinic. J Am Acad Dermatol 2020; 83:1529.</a></li><li><a class="nounderline abstract_t">Jannuzzi RG. Nalbuphine for Treatment of Opioid-induced Pruritus: A Systematic Review of Literature. Clin J Pain 2016; 32:87.</a></li><li><a class="nounderline abstract_t">Kumagai H, Ebata T, Takamori K, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010; 25:1251.</a></li><li><a class="nounderline abstract_t">Fishbane S, Jamal A, Munera C, et al. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. N Engl J Med 2020; 382:222.</a></li><li><a class="nounderline abstract_t">Golpanian RS, Yosipovitch G, Levy C. Use of Butorphanol as Treatment for Cholestatic Itch. Dig Dis Sci 2021; 66:1693.</a></li><li><a class="nounderline abstract_t">Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med 2009; 361:1415.</a></li><li><a class="nounderline abstract_t">Ständer S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010; 5:e10968.</a></li><li><a class="nounderline abstract_t">Vincenzi B, Fratto ME, Santini D, Tonini G. Aprepitant against pruritus in patients with solid tumours. Support Care Cancer 2010; 18:1229.</a></li><li><a class="nounderline abstract_t">Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010; 363:397.</a></li><li><a class="nounderline abstract_t">Mir O, Blanchet B, Goldwasser F. More on aprepitant for erlotinib-induced pruritus. N Engl J Med 2011; 364:487.</a></li><li><a class="nounderline abstract_t">Booken N, Heck M, Nicolay JP, et al. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol 2011; 164:665.</a></li><li><a class="nounderline abstract_t">Torres T, Fernandes I, Selores M, et al. Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues. J Am Acad Dermatol 2012; 66:e14.</a></li><li><a class="nounderline abstract_t">Sharma D, Kwatra SG. Thalidomide for the treatment of chronic refractory pruritus. J Am Acad Dermatol 2016; 74:363.</a></li><li><a class="nounderline abstract_t">Strober B, Sigurgeirsson B, Popp G, et al. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol 2016; 55:401.</a></li><li><a class="nounderline abstract_t">Kimball AB, Luger T, Gottlieb A, et al. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. J Am Acad Dermatol 2016; 75:1156.</a></li><li><a class="nounderline abstract_t">Gottlieb AB, Gordon K, Hsu S, et al. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol 2018; 32:1305.</a></li><li><a class="nounderline abstract_t">Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 2016; 375:2335.</a></li><li><a class="nounderline abstract_t">Hendricks AJ, Yosipovitch G, Shi VY. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. J Dermatolog Treat 2021; 32:19.</a></li><li><a class="nounderline abstract_t">Roh YS, Sutaria N, Biles NF, Kwatra SG. Treatment of Chronic Pruritus With Medical Marijuana. JAMA Dermatol 2021; 157:879.</a></li><li><a class="nounderline abstract_t">White-Chu EF, Reddy M. Dry skin in the elderly: complexities of a common problem. Clin Dermatol 2011; 29:37.</a></li><li><a class="nounderline abstract_t">Boccanfuso SM, Cosmet L, Volpe AR, Bensel A. Skin xerosis. Clinical report on the effect of a moisturizing soap bar. Cutis 1978; 21:703.</a></li><li><a class="nounderline abstract_t">Abbas S, Goldberg JW, Massaro M. Personal cleanser technology and clinical performance. Dermatol Ther 2004; 17 Suppl 1:35.</a></li><li><a class="nounderline abstract_t">Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003; 23:6176.</a></li><li><a class="nounderline abstract_t">Lodén M. The clinical benefit of moisturizers. J Eur Acad Dermatol Venereol 2005; 19:672.</a></li><li><a class="nounderline abstract_t">Draelos ZD. Active agents in common skin care products. Plast Reconstr Surg 2010; 125:719.</a></li><li><a class="nounderline abstract_t">Lipman ZM, Ingrasci G, Yosipovitch G. Approach to the Patient with Chronic Pruritus. Med Clin North Am 2021; 105:699.</a></li><li><a class="nounderline abstract_t">Andrade A, Kuah CY, Martin-Lopez JE, et al. Interventions for chronic pruritus of unknown origin. Cochrane Database Syst Rev 2020; 1:CD013128.</a></li><li><a class="nounderline abstract_t">Feldman SR, Thaçi D, Gooderham M, et al. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 2016; 75:1162.</a></li><li><a class="nounderline abstract_t">Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 2016; 175:902.</a></li><li><a class="nounderline abstract_t">Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020; 396:255.</a></li><li><a class="nounderline abstract_t">Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020; 145:877.</a></li><li><a class="nounderline abstract_t">Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397:2169.</a></li><li><a class="nounderline abstract_t">Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397:2151.</a></li><li><a class="nounderline abstract_t">Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial. JAMA Dermatol 2019; 155:1371.</a></li><li><a class="nounderline abstract_t">Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 2019; 80:913.</a></li><li><a class="nounderline abstract_t">Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117:411.</a></li><li><a class="nounderline abstract_t">Nattkemper LA, Martinez-Escala ME, Gelman AB, et al. Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the Skin. Acta Derm Venereol 2016; 96:894.</a></li><li><a class="nounderline abstract_t">Ständer S, Yosipovitch G, Legat FJ, et al. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. N Engl J Med 2020; 382:706.</a></li><li><a class="nounderline abstract_t">Hashimoto T, Kursewicz CD, Fayne RA, et al. Mechanisms of Itch in Stasis Dermatitis: Significant Role of IL-31 from Macrophages. J Invest Dermatol 2020; 140:850.</a></li><li><a class="nounderline abstract_t">Hashimoto T, Kursewicz CD, Fayne RA, et al. Pathophysiologic mechanisms of itch in bullous pemphigoid. J Am Acad Dermatol 2020; 83:53.</a></li><li><a class="nounderline abstract_t">Kabashima K, Matsumura T, Komazaki H, et al. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. N Engl J Med 2020; 383:141.</a></li><li><a class="nounderline abstract_t">Pariser DM, Bagel J, Lebwohl M, et al. Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial. J Am Acad Dermatol 2020; 82:1314.</a></li><li><a class="nounderline abstract_t">Yosipovitch G, Ständer S, Kerby MB, et al. Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. J Am Acad Dermatol 2018; 78:882.</a></li><li class="breakAll">https://www.biospace.com/article/releases/menlo-therapeutics-announces-results-from-two-phase-3-clinical-trials-of-serlopitant-for-the-treatment-of-pruritus-associated-with-prurigo-nodularisconference-call-today-at-8-30am-edt/ (Accessed on May 24, 2021).</li></ol></div><div id="topicVersionRevision">Topic 131632 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23614588" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical practice. Chronic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23614588" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical practice. Chronic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20026846" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Association between frequency of pruritic symptoms and perceived psychological stress: a Japanese population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069504" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12031029" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17535222" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effectiveness of the nursing programme 'Coping with itch': a randomized controlled study in adults with chronic pruritic skin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20002660" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema - a blinded, randomized, placebo-controlled, crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21796811" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Acupuncture for treating uremic pruritus in patients with end-stage renal disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18856158" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A practical review and update on the management of pruritus sine materia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31063610" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Narrowband ultraviolet B phototherapy improves quality of life of psoriasis and atopic dermatitis patients up to 3 months: Results from an observational multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16297006" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Antihistamines and their role as antipruritics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846147" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chronic pruritus--pathogenesis, clinical aspects and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29033248" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Use of oral antidepressants in patients with chronic pruritus: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18713761" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prophylactic mirtazapine reduces intrathecal morphine-induced pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19197541" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357442" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Low-dose doxepin for treatment of pruritus in patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27206757" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gabapentin and pregabalin for the treatment of chronic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16365250" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Efficacy of gabapentin in the management of pruritus of unknown origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16297008" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Ultraviolet phototherapy for pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20946583" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19886961" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Phototherapy of generalized prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17908139" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Narrow-band ultraviolet B phototherapy in patients with recalcitrant nodular prurigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15965439" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/865585" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Relief of uremic pruritus with ultraviolet phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21668425" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15897170" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Resolution of pruritus secondary to polycythemia vera in a patient treated with narrow-band ultraviolet B phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12410710" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20584258" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Narrow-band ultraviolet B as a potential alternative treatment for resistant psychogenic excoriation: an open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19925596" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Notalgia paresthesica successfully treated with narrow-band UVB: report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20844849" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The management of chronic pruritus in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616389" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Uraemic pruritus responsive to broadband ultraviolet (UV) B therapy does not readily respond to narrowband UVB therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16681573" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A randomised controlled trial on photo(chemo)therapy of subacute prurigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20462660" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antipruritic treatment with systemicμ-opioid receptor antagonists: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30484835" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9800145" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18828971" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Development of peripheral opioid antagonists' new insights into opioid effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3144443" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Reversal of epidural morphine-induced respiratory depression and pruritus with nalbuphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21772138" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pathophysiology of itch and new treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16488311" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Butorphanol for treatment of intractable pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32679280" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Intranasal butorphanol rescue therapy for the treatment of intractable pruritus: A case series from the Johns Hopkins Itch Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26650717" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Nalbuphine for Treatment of Opioid-induced Pruritus: A Systematic Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19926718" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31702883" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32556969" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Use of Butorphanol as Treatment for Cholestatic Itch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797294" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Aprepitant as an antipruritic agent?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20532044" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20544226" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Aprepitant against pruritus in patients with solid tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660413" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Aprepitant for erlotinib-induced pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21288111" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : More on aprepitant for erlotinib-induced pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21039410" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22177649" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26577510" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Thalidomide for the treatment of chronic refractory pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26866518" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27692498" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29512200" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27690741" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31693426" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33835147" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment of Chronic Pruritus With Medical Marijuana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21146730" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Dry skin in the elderly: complexities of a common problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/348407" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Skin xerosis. Clinical report on the effect of a moisturizing soap bar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14728697" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Personal cleanser technology and clinical performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12867500" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16268870" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The clinical benefit of moisturizers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124857" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Active agents in common skin care products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34059246" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Approach to the Patient with Chronic Pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31981369" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Interventions for chronic pruritus of unknown origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27692733" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27423107" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32711801" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31786154" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34023009" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34023008" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31577341" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29410014" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461142" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : IL-31: a new link between T cells and pruritus in atopic skin inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27001482" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the Skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32074418" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31626785" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Mechanisms of Itch in Stasis Dermatitis: Significant Role of IL-31 from Macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31351883" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pathophysiologic mechanisms of itch in bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32640132" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32007513" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29462657" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
